MB
MLTX icon

MPM BioImpact’s MoonLake Immunotherapeutics MLTX Stock Holding History

MPM BioImpact’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8M Buy
+1,811,082
New +$30M 2.61% 13
2025
Q3 		– Sell
-313,571
Closed -$14.8M – 45
2025
Q2 		$14.8M Sell
313,571
-2,478
-0.8% -$101K 2.56% 13
2025
Q1 		$12.3M Buy
316,049
+819
+0.3% +$35.3K 2.12% 17
2024
Q4 		$17.1M Sell
315,230
-33,833
-10% -$1.73M 2.42% 15
2024
Q3 		$17.6M Buy
349,063
+5,828
+2% +$273K 2.64% 13
2024
Q2 		$15.1M Buy
343,235
+47,185
+16% +$2M 2.35% 11
2024
Q1 		$14.9M Buy
296,050
+1,474
+0.5% +$80K 2.39% 12
2023
Q4 		$17.8M Buy
294,576
+386
+0.1% +$19.9K 4.16% 7
2023
Q3 		$16.8M Sell
294,190
-921
-0.3% -$50.8K 4.48% 7
2023
Q2 		$15.1M Buy
+295,111
New +$7.94M 3.03% 12

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.98B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.43B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return